



# Terazosin Hydrochloride Tablets



*IIP-EU-Development Line*

Therapeutic indication: Benign prostatic  
hyperplasia, hypertension




## 1 mg Tablets

One tablet contains:  
1.19 mg Terazosin hydrochloride  
(corresponding to 1 mg Terazosin)  
Weight: 150 mg




## 2 mg Tablets

One tablet contains:  
2.37 mg Terazosin hydrochloride  
(corresponding to 2 mg Terazosin)  
Weight: 150 mg



## 5 mg Tablets

One tablet contains:  
5.94 mg Terazosin hydrochloride  
(corresponding to 5 mg Terazosin)  
Weight: 150 mg



## 10 mg Tablets

One tablet contains:  
11.87 mg Terazosin hydrochloride  
(corresponding to 10 mg  
Terazosin)  
Weight: 150 mg



We expressly point out that these dossiers or marketing authorisations cannot be used in countries where corresponding medicinal products or the application of such products are protected by patent.



### Product Advantages

- cGMP compliant German API manufacturer
- EU development
- cGMP compliant German contract manufacturer
- Sugar-free dosage form
- Exposé with scientific data available upon request



**IIP – Institut für industrielle Pharmazie  
Forschungs- und Entwicklungsgesellschaft mbH**

Management  
Benzstraße 2a  
63741 Aschaffenburg, Germany  
Tel.: 00 49 - (0) 60 21-5 85 93 - 0  
Fax: 00 49 - (0) 60 21-5 85 93 - 28  
E-Mail: [management@iip.de](mailto:management@iip.de)  
[www.iip.de](http://www.iip.de)

Regulatory affairs – Technical department  
Benzstraße 2a  
63741 Aschaffenburg, Germany  
Tel.: 00 49 - (0) 60 21-5 85 93 - 0  
Fax: 00 49 - (0) 60 21-5 85 93 - 28  
E-Mail: [regaffairs@iip.de](mailto:regaffairs@iip.de)  
[www.iip.de](http://www.iip.de)